Tango Therapeutics (TNGX) CEO gets 350K RSUs, 1.65M options grant

Rhea-AI Filing Summary

Tango Therapeutics, Inc. reported that President & CEO and director Malte Peters received new equity awards. On January 8, 2026, he was granted 350,000 restricted stock units (RSUs) of common stock at a grant price of $0.00, increasing his directly held common shares to 367,500. Each RSU represents one share of common stock and will vest over three years: 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to continued service.

He was also granted a stock option for 1,650,000 shares of common stock with an exercise price of $11.06 per share, expiring on January 8, 2036. This option vests over four years, with 25% vesting on January 8, 2027 and the remainder vesting in 36 substantially equal monthly installments thereafter, contingent on continued service, leaving him with 1,650,000 options beneficially owned.

Insights

Executive compensation and governance analyst

Tango’s CEO received sizeable time-vested RSU and option grants, aligning pay with long-term service.

The reporting shows Malte Peters, President & CEO and director of Tango Therapeutics, receiving equity awards rather than selling shares. He was granted 350,000 RSUs of common stock at $0.00 and a stock option covering 1,650,000 shares with a $11.06 exercise price, both reported as directly owned. These awards increase his equity exposure to the company.

The RSUs vest over three years with scheduled dates in 2027, 2028, and 2029, while the option vests over four years starting January 8, 2027 and then in 36 monthly installments until its January 8, 2036 expiration. This structure encourages retention and long-term focus, as much of the potential value depends on continued service and future share price performance.

No information is provided here about the company’s overall share count or prior grants, so the relative dilution impact cannot be assessed from this excerpt alone. Based solely on the disclosed facts, this appears to be a standard equity compensation grant for a senior executive, and thus is best viewed as a neutral, governance-related development.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peters Malte

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MA 02215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		A		350,000(1)	A	$0.00	367,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.06	01/08/2026		A		1,650,000		(2)	01/08/2036	Common Stock	1,650,000	$0.00	1,650,000	D

Explanation of Responses:

1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

2. This option shall vest and become exercisable over a four-year period, with 25% vesting on January 8, 2027 and the remaining option shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

	/s/ Julie Fogarty, as attorney-in-fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the reporting person in the Tango Therapeutics (TNGX) Form 4?

The reporting person is Malte Peters, who serves as a director and as President & CEO of Tango Therapeutics, Inc..

What non-derivative equity award did the Tango Therapeutics CEO receive?

He received 350,000 RSUs of Tango Therapeutics common stock at a grant price of $0.00, bringing his directly held common shares to 367,500 after the grant.

How do the RSUs granted to the Tango Therapeutics CEO vest?

The 350,000 RSUs vest over three years: 33% on February 1, 2027, 33% on February 14, 2028, and 34% on February 12, 2029, subject to his continuous service.

What stock option grant was reported for the Tango Therapeutics (TNGX) CEO?

He was granted a stock option for 1,650,000 shares of common stock with an exercise price of $11.06 per share, expiring on January 8, 2036, and reported as directly owned.

What is the vesting schedule of the CEO’s stock option at Tango Therapeutics?

The option vests over four years: 25% on January 8, 2027, with the remaining shares vesting in 36 substantially equal monthly installments thereafter, conditioned on continued service.

Did the Tango Therapeutics Form 4 indicate any share sales by the CEO?

No share sales were reported. The Form 4 shows acquisitions (code A) of RSUs and stock options, not dispositions of existing shares.